PGNX Insider Trading Activity and SEC Form 4 Filings
PGNX insider trading summary
No open-market insider purchases or sales of Progenics Pharmaceuticals Inc (PGNX) have been reported on SEC Form 4 in the past 12 months.
Latest PGNX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 9, 2019 | Balaji Venkataraman | 10% Owner | Buy | $360K (72,023 @ $4.99) |
| Sep 9, 2019 | Velan Capital, L.P. | 10% Owner | Buy | $360K (72,023 @ $4.99) |
| Sep 9, 2019 | Altiva Management Inc. | 10% Owner | Buy | $360K (72,023 @ $4.99) |
| Sep 9, 2019 | Ryan Melkonian | 10% Owner | Buy | $106K (21,480 @ $4.94) |
| Sep 9, 2019 | Melkonian Capital Management, LLC | 10% Owner | Buy | $106K (21,480 @ $4.94) |
| Sep 9, 2019 | LTE Management, LLC | 10% Owner | Buy | $106K (21,480 @ $4.94) |
| Sep 9, 2019 | LTE Partners, LLC | 10% Owner | Buy | $106K (21,480 @ $4.94) |
| Sep 5, 2019 | LTE Partners, LLC | 10% Owner | Buy | $201K (43,520 @ $4.62) |
| Sep 5, 2019 | Ryan Melkonian | 10% Owner | Buy | $201K (43,520 @ $4.62) |
| Sep 5, 2019 | Melkonian Capital Management, LLC | 10% Owner | Buy | $201K (43,520 @ $4.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.